Compositions and methods for treating Huntington's disease and related disorders
Compositions and methods are provided for the inhibition, treatment and/or prevention of Huntington's disease and related disorders.
1. A method for inhibiting, treating, and/or preventing a polyglutamine disorder in a subject in need thereof, said method comprising reducing the expression of a mutant protein encoded by an allele of a gene associated with the polyglutamine disorder in said subject,
wherein said polyglutamine disorder is characterized by an abnormally high number of cytosine-adenine-guanine (CAG) repeats resulting in an extended polyglutamine tract in the encoded for mutant protein, and
wherein said method comprising administering to the subject a nucleic acid molecule encoding Cas 9 and at least two guide RNA or a nucleic acid molecule encoding said at least two guide RNA,
wherein at least one of the guide RNA comprises a complementary sequence which comprises a sequence immediately 5′ to a protospacer-adjacent motif (PAM) present only on the mutant allele of the gene,
wherein a first guide RNA comprises a sequence which is completely complementary to a sequence within the promoter or 5′ untranslated region of the gene and a second guide RNA comprises a complementary sequence which is completely complementary to a sequence within the first intron of the gene,
wherein the first guide RNA comprises SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, or SEQ ID NO: 386, and
wherein said polyglutamine disorder is Huntington's disorder, said gene is the huntingtin (HTT) gene, and said CAG repeats are contained with the first exon of the HTT gene.
2. The method of claim 1 , wherein said method further comprises administering to the subject at least one donor DNA.
3. The method of claim 1 , wherein said guide RNA are administered as a nucleic acid molecule encoding said guide RNA.
4. The method of claim 3 , wherein said nucleic acid molecules are administered in an expression vector.
5. The method of claim 4 , wherein said expression vector is a viral vector.
6. The method of claim 1 wherein the first guide RNA comprises SEQ ID NO: 379, SEQ ID NO: 380, or SEQ ID NO: 382.
7. The method of claim 1 wherein the first guide RNA comprises SEQ ID NO: 379 or SEQ ID No: 380.
8. A method for reducing the expression of a mutant protein encoded by an allele of a gene associated with a polyglutamine disorder in a cell, said method comprising delivering to the cell a nucleic acid molecule encoding Cas 9 and at least two guide RNA or a nucleic acid molecule encoding said at least two guide RNA,
wherein said polyglutamine disorder is characterized by an abnormally high number of cytosine-adenine-guanine (CAG) repeats resulting in an extended polyglutamine tract in the encoded for mutant protein,
wherein at least one of the guide RNA comprises a complementary sequence which comprises a sequence immediately 5′ to a protospacer-adjacent motif (PAM) present only on the mutant allele of the gene,
wherein a first guide RNA comprises a complementary sequence which is completely complementary to a sequence within the promoter or 5′ untranslated region of the gene and a second guide RNA comprises a complementary sequence which is completely complementary to a sequence within the first intron of the gene,
wherein the first guide RNA comprises SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, or SEQ ID NO: 386, and
wherein said polyglutamine disorder is Huntington's disorder, said gene is the huntingtin (HTT) gene, and said CAG repeats are contained with the first exon of the HTT gene.
9. An isolated guide RNA which comprises SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, or SEQ ID NO: 386.
10. An isolated nucleic acid molecule encoding at least one of the guide RNA of claim 9 .
11. A vector comprising the nucleic acid molecule of claim 10 .
12. The vector of claim 11 , which is a viral vector.
13. The vector of claim 11 , further comprising a nucleic acid molecule encoding Cas9.
14. A composition comprising at least one nucleic acid molecule of claim 10 and a carrier.
15. A composition comprising at least one guide RNA of claim 9 and a carrier.
16. A method for inhibiting, treating, and/or preventing a polyglutamine disorder in a subject in need thereof, said method comprising reducing the expression of a mutant protein encoded by an allele of a gene associated with the polyglutamine disorder in said subject,
wherein said polyglutamine disorder is characterized by an abnormally high number of cytosine-adenine-guanine (CAG) repeats resulting in an extended polyglutamine tract in the encoded for mutant protein,
wherein said method comprising administering to the subject a nucleic acid molecule encoding Cas 9 and at least two guide RNA or a nucleic acid molecule encoding said at least two guide RNA,
wherein at least one of the guide RNA comprises a complementary sequence which comprises a sequence immediately 5′ to a protospacer-adjacent motif (PAM) present only on the mutant allele of the gene,
wherein a first guide RNA comprises a complementary sequence which is completely complementary to a sequence within the promoter or 5′ untranslated region of the gene and a second guide RNA comprises a complementary sequence which is completely complementary to a sequence within the first intron of the gene, and
wherein the second guide RNA comprises SEQ ID NO: 387 or SEQ ID NO: 388 or wherein the first guide RNA comprises SEQ ID NO: 379.
17. The method of claim 16 , wherein the second guide RNA comprises SEQ ID NO: 387.
18. The method of claim 16 , wherein the first guide RNA comprises SEQ ID NO: 379.
19. The method of claim 16 , wherein the first guide RNA comprises SEQ ID NO: 379 and the second guide RNA comprises SEQ ID NO: 387.
20. A method for reducing the expression of a mutant protein encoded by an allele of a gene associated with a polyglutamine disorder in a cell, said method comprising delivering to the cell a nucleic acid molecule encoding Cas9 and at least two guide RNA or a nucleic acid molecule encoding said at least two guide RNA,
wherein said polyglutamine disorder is characterized by an abnormally high number of cytosine-adenine-guanine (CAG) repeats resulting in an extended polyglutamine tract in the encoded for mutant protein,
wherein at least one of the guide RNA comprises a complementary sequence which comprises a sequence immediately 5′ to a protospacer-adjacent motif (PAM) present only on the mutant allele of the gene,
wherein a first guide RNA comprises a targeting sequence which is completely complementary to a sequence within the promoter or 5′ untranslated region of the gene and a second guide RNA comprises a targeting sequence which is completely complementary to a sequence within the first intron of the gene, and
wherein the second guide RNA comprises SEQ ID NO: 387 or SEQ ID NO: 388 or wherein the first guide RNA comprises SEQ ID NO: 379.